Business
Phase I Results
Phase I Results.
About this update from Gunsynd Plc
[{"type":"text","content":"\n Syntopix Group plc\n16 August 2007\n\n\nFor immediate release 16 August 2007\n\n SYNTOPIX GROUP PLC\n\n ('Syntopix' or 'the Company')\n\n\n\nPHASE I TRIAL RESULTS IN ACNE\n\n\n\nSyntopix Group plc (AIM: SYN), the speciality pharmaceutical research and\ndevelopment company focused on dermatological diseases, announces the results\nof a human use Phase I trial that validated the Company's methodology for\ndetermining the potential of compounds as topical treatments for acne, with\npositive and negative controls performing as expected. The study confirmed the\nsafety and tolerability of all three test treatments in the skin environment.\n\n\n\nAll the test treatments exhibited some antibacterial activity, with this\nactivity sustained throughout the trial in one of the three treatment groups.\nFurther optimisation work will be required before the test treatments can\nproceed to later stages of clinical development.\n\n\n\nThe Syntopix test treatments were assessed over 14 days in a double-blind,\nrandomised and controlled trial of 22 healthy volunteers. They were SYN 0017 (an\nantioxidant present in foods and cosmetics), SYN 0401 (an antifungal present in\npersonal healthcare products), and a combination of SYN 0017 and SYN 0016 (an\noxidising agent present in pharmaceutical preparations).\n\n\n\nAll three treatment groups produced positive safety and tolerability data with\nno adverse events being recorded. Additionally, all of the treatments produced a\nsignificant reduction in the number of Propionibacterium acnes (P. acnes) after\nfour hours. P. acnes is a bacterium associated with acne and was being used in\nthe trial as a surrogate marker to indicate clinical activity. For one\ntreatment, four of the seven subjects showed a consistent benefit over the two\nweeks of the study.\n\n\n\nIn addition to further evaluation of these test treatments, Syntopix will\ncontinue to assess other compounds from its library of more than 1100 diverse\ncompounds for topical treatments for acne.\n\n\n\nStephen Jones, Syntopix' CEO, commented: 'Whilst all the test treatments were\nshown to be active in the skin environment, further evaluation and optimisation\nwork is required to maximise their efficacy. We will also continue to evaluate\nother suitable compounds from our extensive library of highly diverse compounds\nfor the topical treatment...